久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Rituxan hits endpoints in late-stage skin disease trial pharmatimes
    June 16, 2019
    Roche has announced that its monoclonal antibody, Rituxan (rituximab), met all primary and secondary endpoints in the Phase III PEMPHIX study.
  • Zerbaxa Meets Primary Endpoints americanpharmaceuticalreview
    September 12, 2018
    Merck announced the pivotal Phase 3 clinical study evaluating the company’s antibiotic Zerbaxa (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP)
  • Ionis Announces Phase 3 NEURO-TTR Study of Inotersen Meets Primary Endpoints americanpharmaceuticalreview
    May 16, 2017
    Ionis Pharmaceuticals announced the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.
PharmaSources Customer Service